logo
PROVIDERS
LABS
CROs
PAYORS
PATIENTS
ABOUT US
Schedule a Demo
Contact Us
scope image
Overview

Comprehensive Multi-Phase Trial Support

Leverage AI-driven pharmacogenomics across Phase I–IV to optimize design, reduce risks, and accelerate market success.
Schedule a Demo Contact us
Overview
Each phase of clinical research presents unique challenges, from establishing safety and dosing in Phase I to confirming efficacy and monitoring long-term safety in Phase IV. PGxAI’s Multi-Phase Support delivers targeted pharmacogenomic insights at every stage, helping CROs and sponsors adapt trial strategies, minimize adverse events, and lay the groundwork for successful regulatory submissions. By integrating genetic, clinical, and real-world data, we ensure data-driven decisions that benefit both investigators and patients throughout the drug development lifecycle.
•
Phase I: Rapid dose escalation, patient stratification, and early detection of genetic factors influencing safety.
•
Phase II: Refined patient enrollment, dosage fine-tuning, and predictive modeling for early efficacy signals.
•
Phase III: Large-scale validation of efficacy and safety, reducing dropout rates with gene-based personalized dosing.
•
Phase IV: Post-marketing surveillance and real-world evidence integration to maintain drug safety and explore new indications.
Key Features
Serving every stakeholder in healthcare
Schedule a Demo Contact Us
1
icon
EDC Compatibility
Use PGx insights to identify individuals with higher or lower metabolic capacity.
Optimize early dosing schedules, reducing adverse events and accelerating safe dose escalation.
2
icon
Phase II Patient Stratification
Pinpoint genetic markers linked to higher response rates.
Improve the odds of detecting statistically significant efficacy signals in smaller cohorts.
3
icon
Phase III Scalability
EHR integration and automated data capture scale seamlessly for large patient populations.
AI-driven monitoring flags adverse events in real time, lowering the risk of late-stage trial failures.
4
icon
Phase IV Real-World Evidence
Continuously refine drug labeling and risk management with large-scale post-marketing genetic data.
Open opportunities for label expansion or additional indications based on PGx-driven findings.
Impact
Clinical and Economic Impact
Schedule a Demo Contact Us
Reduced Time & Cost
Early detection of the right dose and patient group can prevent expensive protocol amendments or protracted enrollment periods.
Lower Dropout & Failure Rates
Tailored dosing and patient selection lead to higher adherence, fewer adverse events, and stronger clinical endpoints.
Regulatory Confidence
Robust genetic and outcome data across all phases improve dossier quality, streamlining interactions with the FDA, EMA, and other agencies.
Competitive Advantage
Offer sponsors a data-rich approach that de-risks each phase, building trust and accelerating drug approvals.
Examples
Examples Across the Phases
Leverage AI-driven pharmacogenomics across Phase I–IV to optimize design, reduce risks, and accelerate market success.
Phase I Oncology Trial
Genotype-based safety screens minimize hematologic toxicities and guide rapid dose escalation.
Phase II Cardiology Study
Targeted enrollment of patients with genetic markers for optimal statin response, speeding up proof-of-concept.
Phase III Psychiatry Program
Reduced dropout by tailoring antidepressant therapy to metabolizer status, leading to higher trial completion rates.
Phase IV Diabetes Surveillance
Real-world genetic data reveals new subpopulations for GLP-1 agonists, informing label expansion.
Whats next
Elevate Every Phase of Your Clinical Research
Contact Our Clinical Team
Discuss phase-specific strategies, pilot integrations, or large-scale deployments.
icon
Request a Demo
See PGxAI’s multi-phase capabilities in action.
icon
Learn More
Explore how automated genetic insights can streamline trial operations and enhance patient safety.
icon